EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Melanoma genomics – will we go beyond BRAF in clinics?

Justyna Mirek, Wiesław Bal, Magdalena Olbryt

Journal of Cancer Research and Clinical Oncology · 28.09.2024 · 150 (9)

DOI: 10.1007/s00432-024-05957-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 28.09.2024. Verfasst von Justyna Mirek und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gli…. Hauptthemen laut MEDLINE: Melanoma, Proto-Oncogene Proteins B-raf, Genomics. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the era of next-generation sequencing, the genetic background of cancer, including melanoma, appears to be thoroughly established. However, evaluating the oncogene BRAF mutation in codon V600 is still the only companion diagnostic genomic test commonly implemented in clinics for molecularly targeted treatment of advanced melanoma. Are we wasting the collected genomic data? Will we implement our current genomic knowledge of melanoma in clinics soon? This question is rather urgent because new therapeutic targets and biomarkers are needed to implement more personalized, patient-tailored therapy in clinics. Here, we provide an update on the molecular background of melanoma, including a description of four already established molecular subtypes: BRAF+, NRAS+, NF1+, and triple WT, as well as relatively new NGS-derived melanoma genes such as PREX2 , ERBB4 , PPP6C , FBXW7 , PIK3CA , and IDH1 . We also present a comparison of genomic profiles obtained in recent years with a focus on the most common melanoma genes. Finally, we propose our melanoma gene panel consisting of 22 genes that, in our opinion, are “must-have” genes in both melanoma-specific genomic tests and pan-cancer tests established to improve the treatment of melanoma further.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaProto-Oncogene Proteins B-rafGenomicsHumansMutationHigh-Throughput Nucleotide SequencingBiomarkers, TumorSkin Neoplasms

Stichwörter der Autor:innen

BRAFGenomic testingGenomicsMelanomaNGS

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, 44-101, Poland.
  • Chemotherapy Day Unit, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, 44-101, Poland.
  • Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, 44-101, Poland. magdalena.olbryt@gliwice.nio.gov.pl.

Zitieren

APA

Mirek, J., Bal, W., & Olbryt, M. (2024). Melanoma genomics – will we go beyond BRAF in clinics?. Journal of Cancer Research and Clinical Oncology, 150(9). https://doi.org/10.1007/s00432-024-05957-2

Vancouver

Mirek J, Bal W, Olbryt M. Melanoma genomics – will we go beyond BRAF in clinics?. Journal of Cancer Research and Clinical Oncology. 2024;150(9). doi:10.1007/s00432-024-05957-2

BibTeX
@article{Mirek2024,
  author = {Mirek, Justyna and Bal, Wiesław and Olbryt, Magdalena},
  title = {Melanoma genomics – will we go beyond BRAF in clinics?},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  volume = {150},
  number = {9},
  doi = {10.1007/s00432-024-05957-2}
}
Kostenlos starten →